50POST — Every State. Every Story. My 50POST ↗
LAWS & TAXES / BRIEFING

Agency notice: FDA says BROMFED-DM was not withdrawn for safety or effectiveness

Federal · applicability depends on the document

50POST news graphic: Agency notice: FDA says BROMFED-DM was not withdrawn for safety or effectiveness
50POST news graphic · story-specific information

The FDA has determined that BROMFED-DM syrup was not withdrawn from sale for reasons of safety or effectiveness.

The agency says it will not begin procedures to withdraw approval of abbreviated new drug applications referring to the product and may continue approving them if they meet relevant legal and regulatory requirements.

Based on the linked record from Federal Register ↗. Our reporting and verification standards.

A federal document is not a determination of how a law applies to you. A published rule may have a separate effective date. Consult the official record for its terms.
Source, dates and supporting record
Source published
Nov 18, 2026
Last checked
Nov 19, 2026, 2:45 PM EST
Record status
Agency notice

Read the original record ↗

Supporting excerpts

The Food and Drug Administration (FDA, Agency, or we) has determined that BROMFED-DM (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) syrup, 2 milligrams (mg)/5 milliliters (mL); 10 mg/5 mL; 30 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness.
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Original source text

The Food and Drug Administration (FDA, Agency, or we) has determined that BROMFED-DM (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) syrup, 2 milligrams (mg)/5 milliliters (mL); 10 mg/5 mL; 30 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: 74d8ae4c842438ff7f321b570d9b3d63e5200e459922624ff22d8de22bcf21c2

Source guidance

Consult the linked document and official PDF. Publication does not by itself establish that a rule is currently in force.

Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.

Something doesn’t look right?

Tell the editor what needs checking. Please avoid personal or sensitive details.

Sign in if needed to submit a report